{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:51:08Z","timestamp":1791543068293,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Xiamen Health and Wellness High-Quality Development Science and Technology Plan, China","award":["2024GZL-GG31"],"award-info":[{"award-number":["2024GZL-GG31"]}]},{"name":"Natural Science Foundation of Fujian Province, China","award":["2024J011443"],"award-info":[{"award-number":["2024J011443"]}]},{"name":"Xiamen Medical Health Key Project","award":["3502Z20244014"],"award-info":[{"award-number":["3502Z20244014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00210-026-05568-3","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:34:13Z","timestamp":1781670853000},"page":"19029-19045","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global research hotspots and evolving themes in chemoresistance of hepatocellular carcinoma: a bibliometric analysis from a pharmacological perspective"],"prefix":"10.1007","volume":"399","author":[{"given":"Lihua","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songbin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhekun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirui","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"5568_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/cancers11040483","volume":"11","author":"C Agnoletto","year":"2019","unstructured":"Agnoletto C, Corr\u00e0 F, Minotti L, Baldassari F, Crudele F, Cook W, Di Leva G, D\u2019Adamo A, Gasparini P, Volinia S (2019) Heterogeneity in circulating tumor cells: the relevance of the stem-cell subset. Cancers 11:36","journal-title":"Cancers"},{"key":"5568_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11864-023-01098-9","volume":"24","author":"B Alawyia","year":"2023","unstructured":"Alawyia B, Constantinou C (2023) Hepatocellular carcinoma: a narrative review on current knowledge and future prospects. Curr Treat Options Oncol 24:711\u2013724","journal-title":"Curr Treat Options Oncol"},{"key":"5568_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/biomedicines13010100","volume":"13","author":"E Anwer","year":"2025","unstructured":"Anwer E, Ajagbe M, Sherif M, Musaibah A, Mahmoud S, Elbanbi A, Abdelnaser A (2025) Gut microbiota secondary metabolites: key roles in GI tract cancers and infectious diseases. Biomedicines 13:35","journal-title":"Biomedicines"},{"key":"5568_CR4","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","volume":"11","author":"M Aria","year":"2017","unstructured":"Aria M, Cuccurullo C (2017) bibliometrix: An R-tool for comprehensive science mapping analysis. J Informet 11:959\u2013975","journal-title":"J Informet"},{"key":"5568_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nmat2992","volume":"10","author":"C Ashley","year":"2011","unstructured":"Ashley C, Carnes E, Phillips G, Padilla D, Durfee P, Brown P, Hanna T, Liu J, Phillips B, Carter M, Carroll N, Jiang X, Dunphy D, Willman C, Petsev D, Evans D, Parikh A, Chackerian B, Wharton W, Peabody D, Brinker C (2011) The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater 10:389\u2013397","journal-title":"Nat Mater"},{"key":"5568_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/ijms21114002","volume":"21","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh M, Zarrabi A, Hushmandi K, Kalantari M, Mohammadinejad R, Javaheri T, Sethi G (2020) Association of the Epithelial-Mesenchymal Transition (EMT) with cisplatin resistance. Int J Mol Sci 21:46","journal-title":"Int J Mol Sci"},{"key":"5568_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/oncsis.2017.72","volume":"6","author":"T Avril","year":"2017","unstructured":"Avril T, Vaul\u00e9ron E, Chevet E (2017) Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers. Oncogenesis 6:14","journal-title":"Oncogenesis"},{"key":"5568_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.mtbio.2025.102135","volume":"34","author":"B Bai","year":"2025","unstructured":"Bai B, Zheng Z, Zhu B, Wu J, Xu Y, Zhong X, Deng W, Wang X, Zhao S, You T, Huang Y, Sun W, Shen X, Lu X (2025) An Fe(III)-covalent organic framework (COF)-sorafenib nanoplatform induces chemo-ferroptosis for enhanced hepatocellular carcinoma immunotherapy. Materials Today Bio 34:16","journal-title":"Materials Today Bio"},{"key":"5568_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e13046","volume":"9","author":"RM Batista-Canino","year":"2023","unstructured":"Batista-Canino RM, Santana-Hernandez L, Medina-Brito P (2023) A scientometric analysis on entrepreneurial intention literature: Delving deeper into local citation. Heliyon 9:e13046","journal-title":"Heliyon"},{"key":"5568_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.prp.2025.155991","volume":"270","author":"S Bolandi","year":"2025","unstructured":"Bolandi S, Dodge S, Zahed Z, Soleimani A, Monirvaghefi K, Ghodsifar M, Ghasemi M, Avval N, Zadeh S, Fazayel S, Morovatshoar R, Barfi V, Behfar Q, Dehghani S (2025) Epigenetic and post-translational modifications in ferroptosis regulation and hepatocellular carcinoma: New frontiers in therapeutic targeting. Pathol Res Pract 270:16","journal-title":"Pathol Res Pract"},{"key":"5568_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.drup.2019.100671","volume":"49","author":"X Cao","year":"2020","unstructured":"Cao X, Hou J, An Q, Assaraf Y, Wang X (2020) Towards the overcoming of anticancer drug resistance mediated by p53 mutations. Drug Resist Update 49:10","journal-title":"Drug Resist Update"},{"key":"5568_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223994","volume":"14","author":"C Chen","year":"2019","unstructured":"Chen C, Song M (2019) Visualizing a field of research: A methodology of systematic scientometric reviews. PLoS ONE 14:e0223994","journal-title":"PLoS ONE"},{"key":"5568_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.cmet.2015.12.004","volume":"23","author":"C Chen","year":"2016","unstructured":"Chen C, Kumar D, Punj V, Xu J, Sher L, Tahara S, Hess S, Machida K (2016) NANOG metabolically reprograms tumor-initiating stem-like cells through tumorigenic changes in oxidative phosphorylation and fatty acid metabolism. Cell Metab 23:206\u2013219","journal-title":"Cell Metab"},{"key":"5568_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CAD.0000000000000572","volume":"29","author":"C Chen","year":"2018","unstructured":"Chen C, Lu L, Yan S, Yi H, Yao H, Wu D, He G, Tao X, Deng X (2018) Autophagy and doxorubicin resistance in cancer. Anticancer Drugs 29:1\u20139","journal-title":"Anticancer Drugs"},{"key":"5568_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12943-021-01466-9","volume":"21","author":"Y Chen","year":"2022","unstructured":"Chen Y, Li L, Lan J, Cui Y, Rao X, Zhao J, Xing T, Ju G, Song G, Lou J, Liang J (2022) CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma. Mol Cancer 21:17","journal-title":"Mol Cancer"},{"key":"5568_CR16","first-page":"14","volume":"16","author":"L Chen","year":"2025","unstructured":"Chen L, Zhu Y, Feng M, Zuo D, Chen G, Ji K (2025) Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody. Front Immunol 16:14","journal-title":"Front Immunol"},{"key":"5568_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/cells8091015","volume":"8","author":"Y Chi","year":"2019","unstructured":"Chi Y, Wang D, Wang J, Yu W, Yang J (2019) Long non-coding RNA in the pathogenesis of cancers. Cells 8:44","journal-title":"Cells"},{"key":"5568_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bcp.2025.116914","volume":"237","author":"C Cives-Losada","year":"2025","unstructured":"Cives-Losada C, Asensio M, Briz O, Chinchilla-T\u00e1bora L, Barranco M, del R\u00edo-Alvarez A, Martinez-Chantar M, Avila M, Cairo S, Armengol C, Marin J, Macias R (2025) Relevance of transportome among the mechanisms of chemoresistance in hepatoblastoma. Biochem Pharmacol 237:20","journal-title":"Biochem Pharmacol"},{"key":"5568_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fonc.2018.00327","volume":"8","author":"F Corr\u00e0","year":"2018","unstructured":"Corr\u00e0 F, Agnoletto C, Minotti L, Baldassari F, Volinia S (2018) The network of non-coding RNAs in cancer drug resistance. Front Oncol 8:25","journal-title":"Front Oncol"},{"key":"5568_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/cells14050318","volume":"14","author":"H Esquer","year":"2025","unstructured":"Esquer H, Zhou Q, Labarbera D (2025) Targeted inhibition of CHD1L by OTI-611 reprograms chemotherapy and targeted therapy-induced cell cycle arrest and suppresses proliferation to produce synergistic antitumor effects in breast and colorectal cancer. Cells 14:20","journal-title":"Cells"},{"key":"5568_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12943-019-1029-8","volume":"18","author":"Y Gong","year":"2019","unstructured":"Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K, Cheng H, Jin K, Ni Q, Yu X, Liu C (2019) The role of necroptosis in cancer biology and therapy. Mol Cancer 18:17","journal-title":"Mol Cancer"},{"key":"5568_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fimmu.2025.1658042","volume":"16","author":"Y Gong","year":"2025","unstructured":"Gong Y, Xiong Y, Gao Y, Song X, Gong Y, Wang D, Liu Z, Yang Y, Lu J, Zou I, Shi X (2025) Verteporfin inhibits the cGAS-STING pathway and improves the tumor microenvironment during cisplatin treatment in hepatocellular carcinoma. Front Immunol 16:12","journal-title":"Front Immunol"},{"key":"5568_CR23","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/sj.onc.1209080","volume":"25","author":"S Gordon","year":"2006","unstructured":"Gordon S, Akopyan G, Garban H, Bonavida B (2006) Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 25:1125\u20131142","journal-title":"Oncogene"},{"key":"5568_CR24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.4143\/crt.2016.572","volume":"50","author":"J Guo","year":"2018","unstructured":"Guo J, Xu B, Han Q, Zhou H, Xia Y, Gong C, Dai X, Li Z, Wu G (2018) Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Res Treat 50:445\u2013460","journal-title":"Cancer Res Treat"},{"key":"5568_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12943-024-02140-6","volume":"23","author":"SB Guo","year":"2024","unstructured":"Guo SB, Meng Y, Lin L, Zhou ZZ, Li HL, Tian XP, Huang WJ (2024) Artificial intelligence alphafold model for molecular biology and drug discovery: a machine-learning-driven informatics investigation. Mol Cancer 23:223","journal-title":"Mol Cancer"},{"key":"5568_CR26","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1097\/JS9.0000000000003668","volume":"112","author":"SB Guo","year":"2026","unstructured":"Guo SB, Liu DY, Fang XJ, Meng Y, Zhou ZZ, Li J, Li M, Luo LL, Li HL, Cai XY, Huang WJ, Tian XP (2026) Current concerns and future directions of large language model ChatGPT in medicine: a machine-learning-driven global-scale bibliometric analysis. Int J Surg 112:2805\u20132822","journal-title":"Int J Surg"},{"key":"5568_CR27","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/jnci\/88.20.1442","volume":"88","author":"C Harris","year":"1996","unstructured":"Harris C (1996) Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. JNCI-J Natl Cancer Inst 88:1442\u20131455","journal-title":"JNCI-J Natl Cancer Inst"},{"key":"5568_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13046-024-02949-5","volume":"43","author":"Y Hu","year":"2024","unstructured":"Hu Y, Dong Z, Liu K (2024) Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J Exp Clin Cancer Res 43:29","journal-title":"J Exp Clin Cancer Res"},{"key":"5568_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/cells14141106","volume":"14","author":"J Jeoung","year":"2025","unstructured":"Jeoung J, Kim W, Jo H, Jeoung D (2025) Circular RNAs as targets for developing anticancer therapeutics. Cells 14:28","journal-title":"Cells"},{"key":"5568_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/cddis.2016.461","volume":"8","author":"F Jin","year":"2017","unstructured":"Jin F, Wang Y, Li M, Zhu Y, Liang H, Wang C, Wang F, Zhang C, Zen K, Li L (2017) MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Cell Death Dis 8:13","journal-title":"Cell Death Dis"},{"key":"5568_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/jso.1129","volume":"78","author":"A Kato","year":"2001","unstructured":"Kato A, Miyazaki M, Ambiru S, Yoshitomi H, Ito H, Nakagawa K, Shimizu H, Yokosuka O, Nakajima N (2001) Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 78:110\u2013115","journal-title":"J Surg Oncol"},{"key":"5568_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41575-021-00508-3","volume":"19","author":"T Lee","year":"2022","unstructured":"Lee T, Guan X, Ma S (2022) Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications. Nat Rev Gastroenterol Hepatol 19:26\u201344","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5568_CR33","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1002\/jcb.26107","volume":"118","author":"Y Li","year":"2017","unstructured":"Li Y, Ye Y, Feng B, Qi Y (2017) Long noncoding RNA lncARSR promotes doxorubicin resistance in hepatocellular carcinoma via modulating PTEN-PI3K\/Akt pathway. J Cell Biochem 118:4498\u20134507","journal-title":"J Cell Biochem"},{"key":"5568_CR34","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1080\/10717544.2022.2094498","volume":"29","author":"B Li","year":"2022","unstructured":"Li B, Shao H, Gao L, Li H, Sheng H, Zhu L (2022) Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: a review. Drug Deliv 29:2130\u20132161","journal-title":"Drug Deliv"},{"key":"5568_CR35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","volume":"2","author":"Y Liaw","year":"2008","unstructured":"Liaw Y, Leung N, Kao J, Piratvisuth T, Gane E, Han K, Guan R, Lau G, Locarnini S, Work CHBG (2008) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hep Intl 2:263\u2013283","journal-title":"Hep Intl"},{"key":"5568_CR36","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"Y Liaw","year":"2012","unstructured":"Liaw Y, Kao J, Piratvisuth T, Chan H, Chien R, Liu C, Gane E, Locarnini S, Lim S, Han K, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou J, Chuang W, Lesmana L, Sollano J, Suh D, Omata M (2012) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hep Intl 6:531\u2013561","journal-title":"Hep Intl"},{"key":"5568_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13045-015-0220-7","volume":"8","author":"G Lou","year":"2015","unstructured":"Lou G, Song X, Yang F, Wu S, Wang J, Chen Z, Liu Y (2015) Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. J Hematol Oncol 8:11","journal-title":"J Hematol Oncol"},{"key":"5568_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fphar.2017.00992","volume":"8","author":"B Lu","year":"2018","unstructured":"Lu B, Chen X, Ying M, He Q, Cao J, Yang B (2018) The role of ferroptosis in cancer development and treatment response. Front Pharmacol 8:8","journal-title":"Front Pharmacol"},{"key":"5568_CR39","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/sj.onc.1210811","volume":"27","author":"S Ma","year":"2008","unstructured":"Ma S, Lee T, Zheng B, Chan K, Guan X (2008) CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt\/PKB survival pathway. Oncogene 27:1749\u20131758","journal-title":"Oncogene"},{"key":"5568_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/cells14141073","volume":"14","author":"X Mao","year":"2025","unstructured":"Mao X, Peng S, Lu Y, Song L (2025) Regulatory functions of microRNAs in cancer stem cells: mechanism, facts, and perspectives. Cells 14:35","journal-title":"Cells"},{"key":"5568_CR41","first-page":"26","volume":"12","author":"J Marin","year":"2020","unstructured":"Marin J, Macias R, Monte M, Romero M, Asensio M, Sanchez-Martin A, Cives-Losada C, Temprano A, Espinosa-Escudero R, Reviejo M, Bohorquez L, Briz O (2020) Molecular bases of drug resistance in hepatocellular carcinoma. Cancers 12:26","journal-title":"Cancers"},{"key":"5568_CR42","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/ijc.1498","volume":"94","author":"A Nies","year":"2001","unstructured":"Nies A, K\u00f6nig J, Pfannschmidt M, Klar E, Hofmann W, Keppler D (2001) Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 94:492\u2013499","journal-title":"Int J Cancer"},{"key":"5568_CR43","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/jcp.49.6.470","volume":"49","author":"Y Soini","year":"1996","unstructured":"Soini Y, Virkajarvi N, Raunio H, Paakko P (1996) Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol 49:470\u2013473","journal-title":"J Clin Pathol"},{"key":"5568_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fimmu.2025.1618342","volume":"16","author":"A Sreekumar","year":"2025","unstructured":"Sreekumar A, Ajith A, Mamouni K, Horuzsko D, Horuzsko A (2025) TREM1 is essential for maintaining stemness of liver cancer stem-like cells in hepatocellular carcinoma. Front Immunol 16:15","journal-title":"Front Immunol"},{"key":"5568_CR45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/cddis.2013.350","volume":"4","author":"X Sui","year":"2013","unstructured":"Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, Wang X, He C, Pan H (2013) Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 4:12","journal-title":"Cell Death Dis"},{"key":"5568_CR46","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.3748\/wjg.v22.i13.3547","volume":"22","author":"J Sun","year":"2016","unstructured":"Sun J, Luo Q, Liu L, Song G (2016) Liver cancer stem cell markers: progression and therapeutic implications. World J Gastroenterol 22:3547\u20133557","journal-title":"World J Gastroenterol"},{"key":"5568_CR47","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/stem.30","volume":"27","author":"S Takaishi","year":"2009","unstructured":"Takaishi S, Okumura T, Tu S, Wang S, Shibata W, Vigneshwaran R, Gordon S, Shimada Y, Wang T (2009) Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27:1006\u20131020","journal-title":"Stem Cells"},{"key":"5568_CR48","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","volume":"41","author":"S Topalian","year":"2023","unstructured":"Topalian S, Forde P, Emens L, Yarchoan M, Smith K, Pardoll D (2023) Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy. Cancer Cell 41:1551\u20131566","journal-title":"Cancer Cell"},{"key":"5568_CR49","first-page":"1239","volume":"40","author":"Z Wang","year":"2025","unstructured":"Wang Z, Wang L, Yin G, Li H, Zhang R, Feng Y, Chang W (2025) Hsa_circ_0088036 promotes tumorigenesis and chemotherapy resistance in hepatocellular carcinoma via the miR-140-3p\/KIF2A axis. Histol Histopathol 40:1239\u20131251","journal-title":"Histol Histopathol"},{"key":"5568_CR50","first-page":"160","volume":"310","author":"Y Xu","year":"2011","unstructured":"Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z, Liu J, Cui Y, Bian X, Bie P, Qian C (2011) MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 310:160\u2013169","journal-title":"Cancer Lett"},{"key":"5568_CR51","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.bbrc.2012.06.048","volume":"423","author":"N Xu","year":"2012","unstructured":"Xu N, Zhang J, Shen C, Luo Y, Xia L, Xue F, Xia Q (2012) Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun 423:826\u2013831","journal-title":"Biochem Biophys Res Commun"},{"key":"5568_CR52","doi-asserted-by":"publisher","first-page":"1519000","DOI":"10.3389\/fphar.2025.1519000","volume":"16","author":"D Yu","year":"2025","unstructured":"Yu D, Hu Y, Ma M, Li W, Zhao X (2025) The landscape of research on ferroptosis under hypoxic conditions: a bibliometric analysis. Front Pharmacol 16:1519000","journal-title":"Front Pharmacol"},{"key":"5568_CR53","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1002\/jcb.26899","volume":"119","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Liu Y, Xu X (2018) Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a\/hexokinase 2 pathway. J Cell Biochem 119:6296\u20136308","journal-title":"J Cell Biochem"},{"key":"5568_CR54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbcan.2020.188441","volume":"1874","author":"C Zhang","year":"2020","unstructured":"Zhang C, Jiang W, Ding J (2020) New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta-Rev Cancer 1874:8","journal-title":"Biochim Biophys Acta-Rev Cancer"},{"key":"5568_CR55","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bcp.2025.116848","volume":"236","author":"J Zhang","year":"2025","unstructured":"Zhang J, Guo H, Gong C, Shen J, Jiang G, Liu J, Liang T, Guo L (2025a) Therapeutic targets in the Wnt signaling pathway: Treating cancer with specificity. Biochem Pharmacol 236:14","journal-title":"Biochem Pharmacol"},{"key":"5568_CR56","first-page":"30","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ji Y, Tu Y, Li Y (2025b) Autophagy in doxorubicin resistance: basic concepts, therapeutic perspectives and clinical translation. Front Immunol 16:30","journal-title":"Front Immunol"},{"key":"5568_CR57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41419-019-2053-8","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Chen E, Tang Y, Mao J, Shen J, Zheng X, Xie S, Zhang S, Wu Y, Liu H, Zhi X, Ma T, Ni H, Chen J, Chai K, Chen W (2019a) miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells. Cell Death Dis 10:13","journal-title":"Cell Death Dis"},{"key":"5568_CR58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12935-019-0898-7","volume":"19","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Wang Y, Zhou W, Chen T, Wu Q, Chutturghoon V, Lin B, Geng L, Yang Z, Zhou L, Zheng S (2019b) YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway. Cancer Cell Int 19:15","journal-title":"Cancer Cell Int"},{"key":"5568_CR59","first-page":"23","volume":"12","author":"X Zhou","year":"2022","unstructured":"Zhou X, Ao X, Jia Z, Li Y, Kuang S, Du C, Zhang J, Wang J, Liu Y (2022) Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications. Front Oncol 12:23","journal-title":"Front Oncol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05568-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05568-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05568-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:02:40Z","timestamp":1791540160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05568-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5568"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05568-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used publicly available data from Web of Science. No formal approval from an institutional ethics board is required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}